[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLZLwsS7mEuebRRzCduLNXI2DoEVEdWkYB-IRIJoXKVA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"St. Petersburg State Pavlov Medical University",[4],51,false,13,0,8976,18,16,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Myelodysplastic Syndromes",7,{"name":18,"count":19},"Hodgkin Lymphoma",5,{"name":21,"count":19},"Acute Myeloid Leukemia",{"name":23,"count":24},"Myeloproliferative Neoplasm",4,{"name":26,"count":24},"Chronic Myeloid Leukemia",{"name":28,"count":24},"Ischemic Heart Disease",{"name":30,"count":24},"Urolithiasis",{"name":32,"count":33},"Biphenotypic Acute Leukemia",3,[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04595929","Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-","2021-10-10","5-Fluorouracil",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05832515","AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis","2025-10-01","Fludarabine Phosphate for",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07074951","Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy","2026-03-10","Immunosuppressive treatment",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06508099","Vitamin A and D Supplementation in Allogeneic HCT","2026-05","Vitamin A",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06931613","Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment","2026-06-01","Nivolumab",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07238712","Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","2026-12-10","Ruxolitinib",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07548866","Comparison of Laryngeal Mask and Tracheal Intubation With and Without Topical Lidocaine Application","2027-01-01","anesthesia of the respiratory tract with lidocaine",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06532084","Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen","2027-05","Sorafenib",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06477549","BeFluBu vs FluBuRux Conditioning in Haploidentical HCT","2028-06","Bendamustine Hydrochloride",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06812858","PD-1 Inhibitors Maintenance for cHL Post-autoHCT","2029-05","Nivolumab, Pembrolizumab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,204,289,336,354,380,398,419,440,458,480,502,529,547,565,583,601,625,651,697,727,753,779,801,829,855,877,899,921,939,957,982,1000,1018,1036,1054,1077,1095,1113,1138,1156,1181,1199,1217,1235,1253,1271,1289,1307,1325,1351,1369,1395],{"intervention":59,"totalTrials":94,"cells":95},8,{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":97,"activeCount":9},[],{"trials":99,"activeCount":9},[],{"trials":101,"activeCount":165,"soonestReadout":58},[102,116,127,138,149,159,173,184],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT04981899","A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed\u002FRefractory Hodgkin Lymphoma","UNKNOWN",[87,88],"2023-10-01","2024-10-01","2021-03-01",30,[18],[59,113,114,115],"Ifosfamide","Carboplatin","Etoposide",{"nctId":56,"briefTitle":57,"status":117,"phases":118,"primaryCompletion":58,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":126},"ENROLLING_BY_INVITATION",[88],"2027-06-01","2022-06-01",20,[123,124,59,125],"Relapsed or Refractory Hodgkin Lymphoma","Children","Autologous Haemopoietic Stem Cell Transplant",[59],{"nctId":128,"briefTitle":129,"status":117,"phases":130,"primaryCompletion":131,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT06871007","Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma",[87,88],"2029-09-01","2031-09-01","2024-09-01",22,[136,124,59],"Primary Mediastinal (Thymic) Large B-cell Lymphoma",[59],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":12,"conditions":145,"interventions":146},"NCT03381118","Haploidentical Lymphocytes With Nivolumab\u002FAra-C as Consolidation in Elderly AML Patients","TERMINATED",[88],"2018-09-30","2017-06-30",[21],[147,59,147,59,148],"Cytarabine","G-CSF mobilized HLA-haploidentical donor PBSC",{"nctId":150,"briefTitle":151,"status":105,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":110,"conditions":155,"interventions":157},"NCT03292263","ASCT With Nivolumab in Patients With Multiple Myeloma",[87,88],"2024-12-30","2017-04-24",[156],"Multiple Myeloma",[158,59],"Melphalan",{"nctId":160,"briefTitle":161,"status":141,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT03259516","Nivolumab With Chemotherapy in Refractory MDS",[87,88],"2018-12-25","2017-05-25",2,[15],[59,168,169,170,147,171,172,158],"Azacitidine","Fludarabine","Cyclophosphamide","all trans retinoic acid","Sildenafil",{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":110,"conditions":181,"interventions":183},"NCT03343652","A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed\u002FRefractory Hodgkin's Lymphoma","COMPLETED",[87,88],"2019-03-27","2020-03-27","2017-05-27",[182],"Hodgkin's Lymphoma",[59,79],{"nctId":185,"briefTitle":186,"status":176,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":110,"conditions":190,"interventions":192},"NCT03259529","Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r\u002Fr DLBCL",[87,88],"2020-01-27","2017-03-27",[191],"Diffuse Large B Cell Lymphoma",[193,194,195,196,59,197],"Bendamustine hydrochloride","Gemcitabine 500 mg","Gemcitabine 700 mg","Gemcitabine 1000 mg","Rituximab",{"trials":199,"activeCount":9},[],{"trials":201,"activeCount":9},[],{"trials":203,"activeCount":9},[],{"intervention":64,"totalTrials":205,"cells":206},6,{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":165,"soonestReadout":63},[213,225,236,249,264,274],{"nctId":61,"briefTitle":62,"status":214,"phases":215,"primaryCompletion":63,"completion":63,"start":216,"enrollment":217,"conditions":218,"interventions":223},"RECRUITING",[88],"2025-05-10",60,[219,26,220,221,222],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes (MDS)","Myeloprolipherative Neoplsm","Atypical Chronic Myeloid Leukemia",[64,224],"Abatacept",{"nctId":226,"briefTitle":227,"status":141,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":165,"conditions":231,"interventions":233},"NCT04269850","Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD",[87,88],"2024-11-27","2019-09-01",[232],"Intestinal GVHD",[234,64,235],"allogeneic fecal microbiota","Methylprednisone",{"nctId":237,"briefTitle":238,"status":176,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":121,"conditions":243,"interventions":246},"NCT02806375","PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis",[87,88],"2018-12","2019-04","2016-01",[244,245],"Primary Myelofibrosis","Myeloproliferative Disorders",[247,248,170,64,64],"Busulfan","Fludarabine monophosphate",{"nctId":250,"briefTitle":251,"status":176,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":261},"NCT04669210","PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT",[88],"2023-02-27","2025-03-28","2020-11-03",128,[258,259,21,260],"Graft-versus-host-disease","Stem Cell Transplant Complications","Acute Lymphoid Leukemia",[64,262,263],"Tacrolimus","Mycophenolate Mofetil",{"nctId":265,"briefTitle":266,"status":176,"phases":267,"primaryCompletion":240,"completion":241,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT02997280","Ruxolitinib for Steroid-refractory GVHD",[88],"2016-08",75,[271],"Graft Vs Host Disease",[273],"Ruxolitinib Oral",{"nctId":76,"briefTitle":77,"status":214,"phases":275,"primaryCompletion":78,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":282},[88],"2029-06","2024-06-21",220,[280,21,32,281,23,15],"Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[79,64],{"trials":284,"activeCount":9},[],{"trials":286,"activeCount":9},[],{"trials":288,"activeCount":9},[],{"intervention":79,"totalTrials":19,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":292,"activeCount":9},[],{"trials":294,"activeCount":9},[],{"trials":296,"activeCount":329,"soonestReadout":78},[297,309,313,321,325],{"nctId":298,"briefTitle":299,"status":176,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":307},"NCT04942730","Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)",[88],"2024-04-30","2021-01-21",50,[305,306,32,281,15,23],"Leukemia, Acute Lymphoblastic","Myeloid Leukemia, Acute",[169,79,247,170,263,308],"Tacrolimus 5Mg Cap",{"nctId":76,"briefTitle":77,"status":214,"phases":310,"primaryCompletion":78,"completion":276,"start":277,"enrollment":278,"conditions":311,"interventions":312},[88],[280,21,32,281,23,15],[79,64],{"nctId":314,"briefTitle":315,"status":176,"phases":316,"primaryCompletion":317,"completion":317,"start":302,"enrollment":303,"conditions":318,"interventions":319},"NCT04943757","Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies",[88],"2024-05-30",[306,26,15,23],[79,320],"Cyclophosphamid",{"nctId":174,"briefTitle":175,"status":176,"phases":322,"primaryCompletion":178,"completion":179,"start":180,"enrollment":110,"conditions":323,"interventions":324},[87,88],[182],[59,79],{"nctId":185,"briefTitle":186,"status":176,"phases":326,"primaryCompletion":188,"completion":188,"start":189,"enrollment":110,"conditions":327,"interventions":328},[87,88],[191],[193,194,195,196,59,197],1,{"trials":331,"activeCount":9},[],{"trials":333,"activeCount":9},[],{"trials":335,"activeCount":9},[],{"intervention":224,"totalTrials":329,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":339,"activeCount":9},[],{"trials":341,"activeCount":9},[],{"trials":343,"activeCount":329,"soonestReadout":63},[344],{"nctId":61,"briefTitle":62,"status":214,"phases":345,"primaryCompletion":63,"completion":63,"start":216,"enrollment":217,"conditions":346,"interventions":347},[88],[219,26,220,221,222],[64,224],{"trials":349,"activeCount":9},[],{"trials":351,"activeCount":9},[],{"trials":353,"activeCount":9},[],{"intervention":355,"totalTrials":329,"cells":356},"Nivo-AVD",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":358,"activeCount":9},[],{"trials":360,"activeCount":9},[],{"trials":362,"activeCount":329,"soonestReadout":367},[363],{"nctId":364,"briefTitle":365,"status":214,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT07234487","Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL",[88],"2029-10","2030-10","2024-10-14",178,[18],[355,373],"BEACOPP-like",{"trials":375,"activeCount":9},[],{"trials":377,"activeCount":9},[],{"trials":379,"activeCount":9},[],{"intervention":373,"totalTrials":329,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":392,"PHASE4":394,"NA":396},{"trials":383,"activeCount":9},[],{"trials":385,"activeCount":9},[],{"trials":387,"activeCount":329,"soonestReadout":367},[388],{"nctId":364,"briefTitle":365,"status":214,"phases":389,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":390,"interventions":391},[88],[18],[355,373],{"trials":393,"activeCount":9},[],{"trials":395,"activeCount":9},[],{"trials":397,"activeCount":9},[],{"intervention":84,"totalTrials":329,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":401,"activeCount":9},[],{"trials":403,"activeCount":9},[],{"trials":405,"activeCount":329,"soonestReadout":83},[406],{"nctId":81,"briefTitle":82,"status":214,"phases":407,"primaryCompletion":83,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},[88],"2030-09","2024-01-09",83,[18],[84],{"trials":414,"activeCount":9},[],{"trials":416,"activeCount":9},[],{"trials":418,"activeCount":9},[],{"intervention":54,"totalTrials":329,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":422,"activeCount":9},[],{"trials":424,"activeCount":9},[],{"trials":426,"activeCount":329,"soonestReadout":53},[427],{"nctId":51,"briefTitle":52,"status":214,"phases":428,"primaryCompletion":53,"completion":73,"start":429,"enrollment":278,"conditions":430,"interventions":432},[88],"2024-05-15",[280,21,32,281,26,15,221,431],"Non-hodgkin Lymphoma",[54,433],"Vitamin D3",{"trials":435,"activeCount":9},[],{"trials":437,"activeCount":9},[],{"trials":439,"activeCount":9},[],{"intervention":433,"totalTrials":329,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":443,"activeCount":9},[],{"trials":445,"activeCount":9},[],{"trials":447,"activeCount":329,"soonestReadout":53},[448],{"nctId":51,"briefTitle":52,"status":214,"phases":449,"primaryCompletion":53,"completion":73,"start":429,"enrollment":278,"conditions":450,"interventions":451},[88],[280,21,32,281,26,15,221,431],[54,433],{"trials":453,"activeCount":9},[],{"trials":455,"activeCount":9},[],{"trials":457,"activeCount":9},[],{"intervention":74,"totalTrials":329,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":461,"activeCount":9},[],{"trials":463,"activeCount":9},[],{"trials":465,"activeCount":329,"soonestReadout":73},[466],{"nctId":71,"briefTitle":72,"status":214,"phases":467,"primaryCompletion":73,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":473},[88],"2028-05","2024-05-22",88,[472,15,26,23],"Acute Myeloid Leukemia, in Relapse",[74],{"trials":475,"activeCount":9},[],{"trials":477,"activeCount":9},[],{"trials":479,"activeCount":9},[],{"intervention":44,"totalTrials":329,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":483,"activeCount":9},[],{"trials":485,"activeCount":329,"soonestReadout":43},[486],{"nctId":41,"briefTitle":42,"status":214,"phases":487,"primaryCompletion":43,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},[87],"2026-12-01","2020-10-01",200,[492],"Multiple Sclerosis",[44],{"trials":495,"activeCount":9},[],{"trials":497,"activeCount":9},[],{"trials":499,"activeCount":9},[],{"trials":501,"activeCount":9},[],{"intervention":39,"totalTrials":329,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":514},{"trials":505,"activeCount":9},[],{"trials":507,"activeCount":9},[],{"trials":509,"activeCount":9},[],{"trials":511,"activeCount":9},[],{"trials":513,"activeCount":9},[],{"trials":515,"activeCount":329,"soonestReadout":38},[516],{"nctId":36,"briefTitle":37,"status":214,"phases":517,"primaryCompletion":38,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":524},[91],"2029-01-10","2020-02-10",304,[522,523],"Peritoneal Carcinomatosis","Gastric Cancer",[39,525,526,527,528],"Leucovorin","Oxaliplatin","Docetaxel","Adjuvant chemotherapy",{"intervention":525,"totalTrials":329,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":532,"activeCount":9},[],{"trials":534,"activeCount":9},[],{"trials":536,"activeCount":9},[],{"trials":538,"activeCount":9},[],{"trials":540,"activeCount":9},[],{"trials":542,"activeCount":329,"soonestReadout":38},[543],{"nctId":36,"briefTitle":37,"status":214,"phases":544,"primaryCompletion":38,"completion":518,"start":519,"enrollment":520,"conditions":545,"interventions":546},[91],[522,523],[39,525,526,527,528],{"intervention":526,"totalTrials":329,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":550,"activeCount":9},[],{"trials":552,"activeCount":9},[],{"trials":554,"activeCount":9},[],{"trials":556,"activeCount":9},[],{"trials":558,"activeCount":9},[],{"trials":560,"activeCount":329,"soonestReadout":38},[561],{"nctId":36,"briefTitle":37,"status":214,"phases":562,"primaryCompletion":38,"completion":518,"start":519,"enrollment":520,"conditions":563,"interventions":564},[91],[522,523],[39,525,526,527,528],{"intervention":527,"totalTrials":329,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":568,"activeCount":9},[],{"trials":570,"activeCount":9},[],{"trials":572,"activeCount":9},[],{"trials":574,"activeCount":9},[],{"trials":576,"activeCount":9},[],{"trials":578,"activeCount":329,"soonestReadout":38},[579],{"nctId":36,"briefTitle":37,"status":214,"phases":580,"primaryCompletion":38,"completion":518,"start":519,"enrollment":520,"conditions":581,"interventions":582},[91],[522,523],[39,525,526,527,528],{"intervention":528,"totalTrials":329,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":586,"activeCount":9},[],{"trials":588,"activeCount":9},[],{"trials":590,"activeCount":9},[],{"trials":592,"activeCount":9},[],{"trials":594,"activeCount":9},[],{"trials":596,"activeCount":329,"soonestReadout":38},[597],{"nctId":36,"briefTitle":37,"status":214,"phases":598,"primaryCompletion":38,"completion":518,"start":519,"enrollment":520,"conditions":599,"interventions":600},[91],[522,523],[39,525,526,527,528],{"intervention":49,"totalTrials":329,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":613},{"trials":604,"activeCount":9},[],{"trials":606,"activeCount":9},[],{"trials":608,"activeCount":9},[],{"trials":610,"activeCount":9},[],{"trials":612,"activeCount":9},[],{"trials":614,"activeCount":329,"soonestReadout":48},[615],{"nctId":46,"briefTitle":47,"status":214,"phases":616,"primaryCompletion":48,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":624},[91],"2027-12-10","2013-03-10",240,[621,622,623],"Primary IgA-nephropathy","High-risk","Caucasians",[49],{"intervention":69,"totalTrials":329,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":628,"activeCount":9},[],{"trials":630,"activeCount":9},[],{"trials":632,"activeCount":9},[],{"trials":634,"activeCount":9},[],{"trials":636,"activeCount":9},[],{"trials":638,"activeCount":329,"soonestReadout":68},[639],{"nctId":66,"briefTitle":67,"status":640,"phases":641,"primaryCompletion":68,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":650},"ACTIVE_NOT_RECRUITING",[],"2027-02-01","2026-04-01",150,[646,647,648,649],"Comparison of Airway Management Techniques in Functional Endoscopic Sinus Surgery","Rhinosinusitis With Polyps","Deviated Nasal Septum","Osteoma of the Paranasal Sinuses",[69],{"intervention":247,"totalTrials":24,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":654,"activeCount":9},[],{"trials":656,"activeCount":9},[],{"trials":658,"activeCount":9},[659,663,667,680],{"nctId":298,"briefTitle":299,"status":176,"phases":660,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":661,"interventions":662},[88],[305,306,32,281,15,23],[169,79,247,170,263,308],{"nctId":237,"briefTitle":238,"status":176,"phases":664,"primaryCompletion":240,"completion":241,"start":242,"enrollment":121,"conditions":665,"interventions":666},[87,88],[244,245],[247,248,170,64,64],{"nctId":668,"briefTitle":669,"status":141,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":677},"NCT02627573","Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT",[88],"2019-04-03","2015-07",32,[675,15,676],"Leukemia, Chronic Myeloid","Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",[247,248,262,678,170,679],"Mycophenolate mofetil","Thymoglobulin",{"nctId":681,"briefTitle":682,"status":176,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT02799147","GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia",[87,88],"2020-11","2016-06",27,[305,21,688],"Mixed-Lineage Acute Leukemias",[248,247,690],"Bendamustine",{"trials":692,"activeCount":9},[],{"trials":694,"activeCount":9},[],{"trials":696,"activeCount":9},[],{"intervention":170,"totalTrials":24,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":700,"activeCount":9},[],{"trials":702,"activeCount":9},[],{"trials":704,"activeCount":9},[705,709,713,717],{"nctId":298,"briefTitle":299,"status":176,"phases":706,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":707,"interventions":708},[88],[305,306,32,281,15,23],[169,79,247,170,263,308],{"nctId":237,"briefTitle":238,"status":176,"phases":710,"primaryCompletion":240,"completion":241,"start":242,"enrollment":121,"conditions":711,"interventions":712},[87,88],[244,245],[247,248,170,64,64],{"nctId":668,"briefTitle":669,"status":141,"phases":714,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":715,"interventions":716},[88],[675,15,676],[247,248,262,678,170,679],{"nctId":160,"briefTitle":161,"status":141,"phases":718,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":719,"interventions":720},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":722,"activeCount":9},[],{"trials":724,"activeCount":9},[],{"trials":726,"activeCount":9},[],{"intervention":263,"totalTrials":33,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":730,"activeCount":9},[],{"trials":732,"activeCount":9},[],{"trials":734,"activeCount":9},[735,739,743],{"nctId":298,"briefTitle":299,"status":176,"phases":736,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":737,"interventions":738},[88],[305,306,32,281,15,23],[169,79,247,170,263,308],{"nctId":250,"briefTitle":251,"status":176,"phases":740,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":741,"interventions":742},[88],[258,259,21,260],[64,262,263],{"nctId":668,"briefTitle":669,"status":141,"phases":744,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":745,"interventions":746},[88],[675,15,676],[247,248,262,678,170,679],{"trials":748,"activeCount":9},[],{"trials":750,"activeCount":9},[],{"trials":752,"activeCount":9},[],{"intervention":248,"totalTrials":33,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":756,"activeCount":9},[],{"trials":758,"activeCount":9},[],{"trials":760,"activeCount":9},[761,765,769],{"nctId":237,"briefTitle":238,"status":176,"phases":762,"primaryCompletion":240,"completion":241,"start":242,"enrollment":121,"conditions":763,"interventions":764},[87,88],[244,245],[247,248,170,64,64],{"nctId":668,"briefTitle":669,"status":141,"phases":766,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":767,"interventions":768},[88],[675,15,676],[247,248,262,678,170,679],{"nctId":681,"briefTitle":682,"status":176,"phases":770,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":771,"interventions":772},[87,88],[305,21,688],[248,247,690],{"trials":774,"activeCount":9},[],{"trials":776,"activeCount":9},[],{"trials":778,"activeCount":9},[],{"intervention":169,"totalTrials":165,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":782,"activeCount":9},[],{"trials":784,"activeCount":9},[],{"trials":786,"activeCount":9},[787,791],{"nctId":298,"briefTitle":299,"status":176,"phases":788,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":789,"interventions":790},[88],[305,306,32,281,15,23],[169,79,247,170,263,308],{"nctId":160,"briefTitle":161,"status":141,"phases":792,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":793,"interventions":794},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":796,"activeCount":9},[],{"trials":798,"activeCount":9},[],{"trials":800,"activeCount":9},[],{"intervention":197,"totalTrials":165,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":817,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":804,"activeCount":9},[],{"trials":806,"activeCount":9},[807],{"nctId":808,"briefTitle":809,"status":105,"phases":810,"primaryCompletion":811,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":816},"NCT05078177","Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis",[87],"2022-12-21","2024-12-21","2020-12-21",40,[492],[197],{"trials":818,"activeCount":9},[819],{"nctId":185,"briefTitle":186,"status":176,"phases":820,"primaryCompletion":188,"completion":188,"start":189,"enrollment":110,"conditions":821,"interventions":822},[87,88],[191],[193,194,195,196,59,197],{"trials":824,"activeCount":9},[],{"trials":826,"activeCount":9},[],{"trials":828,"activeCount":9},[],{"intervention":234,"totalTrials":165,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":832,"activeCount":9},[],{"trials":834,"activeCount":9},[835],{"nctId":836,"briefTitle":837,"status":141,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":121,"conditions":841,"interventions":842},"NCT04203017","Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis",[87],"2023-11-29","2019-06-01",[492],[234],{"trials":844,"activeCount":9},[845],{"nctId":226,"briefTitle":227,"status":141,"phases":846,"primaryCompletion":229,"completion":229,"start":230,"enrollment":165,"conditions":847,"interventions":848},[87,88],[232],[234,64,235],{"trials":850,"activeCount":9},[],{"trials":852,"activeCount":9},[],{"trials":854,"activeCount":9},[],{"intervention":262,"totalTrials":165,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":858,"activeCount":9},[],{"trials":860,"activeCount":9},[],{"trials":862,"activeCount":9},[863,867],{"nctId":250,"briefTitle":251,"status":176,"phases":864,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":865,"interventions":866},[88],[258,259,21,260],[64,262,263],{"nctId":668,"briefTitle":669,"status":141,"phases":868,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":869,"interventions":870},[88],[675,15,676],[247,248,262,678,170,679],{"trials":872,"activeCount":9},[],{"trials":874,"activeCount":9},[],{"trials":876,"activeCount":9},[],{"intervention":147,"totalTrials":165,"cells":878},{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":880,"activeCount":9},[],{"trials":882,"activeCount":9},[],{"trials":884,"activeCount":9},[885,889],{"nctId":139,"briefTitle":140,"status":141,"phases":886,"primaryCompletion":143,"completion":143,"start":144,"enrollment":12,"conditions":887,"interventions":888},[88],[21],[147,59,147,59,148],{"nctId":160,"briefTitle":161,"status":141,"phases":890,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":891,"interventions":892},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":894,"activeCount":9},[],{"trials":896,"activeCount":9},[],{"trials":898,"activeCount":9},[],{"intervention":158,"totalTrials":165,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":902,"activeCount":9},[],{"trials":904,"activeCount":9},[],{"trials":906,"activeCount":9},[907,911],{"nctId":150,"briefTitle":151,"status":105,"phases":908,"primaryCompletion":153,"completion":153,"start":154,"enrollment":110,"conditions":909,"interventions":910},[87,88],[156],[158,59],{"nctId":160,"briefTitle":161,"status":141,"phases":912,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":913,"interventions":914},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":916,"activeCount":9},[],{"trials":918,"activeCount":9},[],{"trials":920,"activeCount":9},[],{"intervention":308,"totalTrials":329,"cells":922},{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":924,"activeCount":9},[],{"trials":926,"activeCount":9},[],{"trials":928,"activeCount":9},[929],{"nctId":298,"briefTitle":299,"status":176,"phases":930,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":931,"interventions":932},[88],[305,306,32,281,15,23],[169,79,247,170,263,308],{"trials":934,"activeCount":9},[],{"trials":936,"activeCount":9},[],{"trials":938,"activeCount":9},[],{"intervention":235,"totalTrials":329,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":942,"activeCount":9},[],{"trials":944,"activeCount":9},[],{"trials":946,"activeCount":9},[947],{"nctId":226,"briefTitle":227,"status":141,"phases":948,"primaryCompletion":229,"completion":229,"start":230,"enrollment":165,"conditions":949,"interventions":950},[87,88],[232],[234,64,235],{"trials":952,"activeCount":9},[],{"trials":954,"activeCount":9},[],{"trials":956,"activeCount":9},[],{"intervention":958,"totalTrials":329,"cells":959},"Prolgolimab",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":961,"activeCount":9},[],{"trials":963,"activeCount":9},[],{"trials":965,"activeCount":9},[966],{"nctId":967,"briefTitle":968,"status":105,"phases":969,"primaryCompletion":970,"completion":971,"start":972,"enrollment":110,"conditions":973,"interventions":974},"NCT05757466","Prolgolimab Monotherapy or in Combination With Bendamustine for r\u002Fr Classical Hodgkin Lymphoma",[88],"2024-03-10","2025-03-10","2023-04-19",[18],[958,975],"Combination with prolgolimab and bendamustine",{"trials":977,"activeCount":9},[],{"trials":979,"activeCount":9},[],{"trials":981,"activeCount":9},[],{"intervention":975,"totalTrials":329,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":985,"activeCount":9},[],{"trials":987,"activeCount":9},[],{"trials":989,"activeCount":9},[990],{"nctId":967,"briefTitle":968,"status":105,"phases":991,"primaryCompletion":970,"completion":971,"start":972,"enrollment":110,"conditions":992,"interventions":993},[88],[18],[958,975],{"trials":995,"activeCount":9},[],{"trials":997,"activeCount":9},[],{"trials":999,"activeCount":9},[],{"intervention":113,"totalTrials":329,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":9},[],{"trials":1005,"activeCount":9},[],{"trials":1007,"activeCount":9},[1008],{"nctId":103,"briefTitle":104,"status":105,"phases":1009,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":1010,"interventions":1011},[87,88],[18],[59,113,114,115],{"trials":1013,"activeCount":9},[],{"trials":1015,"activeCount":9},[],{"trials":1017,"activeCount":9},[],{"intervention":114,"totalTrials":329,"cells":1019},{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1021,"activeCount":9},[],{"trials":1023,"activeCount":9},[],{"trials":1025,"activeCount":9},[1026],{"nctId":103,"briefTitle":104,"status":105,"phases":1027,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":1028,"interventions":1029},[87,88],[18],[59,113,114,115],{"trials":1031,"activeCount":9},[],{"trials":1033,"activeCount":9},[],{"trials":1035,"activeCount":9},[],{"intervention":115,"totalTrials":329,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1039,"activeCount":9},[],{"trials":1041,"activeCount":9},[],{"trials":1043,"activeCount":9},[1044],{"nctId":103,"briefTitle":104,"status":105,"phases":1045,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":1046,"interventions":1047},[87,88],[18],[59,113,114,115],{"trials":1049,"activeCount":9},[],{"trials":1051,"activeCount":9},[],{"trials":1053,"activeCount":9},[],{"intervention":1055,"totalTrials":329,"cells":1056},"Nivolumab 40 mg in 4 ml",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1058,"activeCount":9},[],{"trials":1060,"activeCount":9},[],{"trials":1062,"activeCount":9},[1063],{"nctId":1064,"briefTitle":1065,"status":176,"phases":1066,"primaryCompletion":1067,"completion":1067,"start":1068,"enrollment":110,"conditions":1069,"interventions":1070},"NCT03343665","Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed\u002FRefractory Hodgkins Lymphoma",[87,88],"2019-12-20","2017-08-01",[18],[1055],{"trials":1072,"activeCount":9},[],{"trials":1074,"activeCount":9},[],{"trials":1076,"activeCount":9},[],{"intervention":148,"totalTrials":329,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":9},[],{"trials":1082,"activeCount":9},[],{"trials":1084,"activeCount":9},[1085],{"nctId":139,"briefTitle":140,"status":141,"phases":1086,"primaryCompletion":143,"completion":143,"start":144,"enrollment":12,"conditions":1087,"interventions":1088},[88],[21],[147,59,147,59,148],{"trials":1090,"activeCount":9},[],{"trials":1092,"activeCount":9},[],{"trials":1094,"activeCount":9},[],{"intervention":679,"totalTrials":329,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":9},[],{"trials":1100,"activeCount":9},[],{"trials":1102,"activeCount":9},[1103],{"nctId":668,"briefTitle":669,"status":141,"phases":1104,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":1105,"interventions":1106},[88],[675,15,676],[247,248,262,678,170,679],{"trials":1108,"activeCount":9},[],{"trials":1110,"activeCount":9},[],{"trials":1112,"activeCount":9},[],{"intervention":1114,"totalTrials":329,"cells":1115},"Allogeneic platelet lysate eye drops",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1117,"activeCount":9},[],{"trials":1119,"activeCount":9},[],{"trials":1121,"activeCount":9},[1122],{"nctId":1123,"briefTitle":1124,"status":176,"phases":1125,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1131},"NCT05311514","Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease",[88],"2024-11-29","2021-04-01",38,[1130],"Ocular Graft-versus-host Disease",[1114],{"trials":1133,"activeCount":9},[],{"trials":1135,"activeCount":9},[],{"trials":1137,"activeCount":9},[],{"intervention":690,"totalTrials":329,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1141,"activeCount":9},[],{"trials":1143,"activeCount":9},[],{"trials":1145,"activeCount":9},[1146],{"nctId":681,"briefTitle":682,"status":176,"phases":1147,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":1148,"interventions":1149},[87,88],[305,21,688],[248,247,690],{"trials":1151,"activeCount":9},[],{"trials":1153,"activeCount":9},[],{"trials":1155,"activeCount":9},[],{"intervention":1157,"totalTrials":329,"cells":1158},"Prophylactic Donor lymphocytes infusions",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1160,"activeCount":9},[],{"trials":1162,"activeCount":9},[],{"trials":1164,"activeCount":9},[1165],{"nctId":1166,"briefTitle":1167,"status":176,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1127,"enrollment":303,"conditions":1171,"interventions":1173},"NCT05009719","Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy",[87,88],"2023-04-01","2024-04-01",[1172],"Hematologic Malignancy",[1157,1174],"Preventive Donor lymphocytes infusions",{"trials":1176,"activeCount":9},[],{"trials":1178,"activeCount":9},[],{"trials":1180,"activeCount":9},[],{"intervention":1174,"totalTrials":329,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1184,"activeCount":9},[],{"trials":1186,"activeCount":9},[],{"trials":1188,"activeCount":9},[1189],{"nctId":1166,"briefTitle":1167,"status":176,"phases":1190,"primaryCompletion":1169,"completion":1170,"start":1127,"enrollment":303,"conditions":1191,"interventions":1192},[87,88],[1172],[1157,1174],{"trials":1194,"activeCount":9},[],{"trials":1196,"activeCount":9},[],{"trials":1198,"activeCount":9},[],{"intervention":320,"totalTrials":329,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":9},[],{"trials":1204,"activeCount":9},[],{"trials":1206,"activeCount":9},[1207],{"nctId":314,"briefTitle":315,"status":176,"phases":1208,"primaryCompletion":317,"completion":317,"start":302,"enrollment":303,"conditions":1209,"interventions":1210},[88],[306,26,15,23],[79,320],{"trials":1212,"activeCount":9},[],{"trials":1214,"activeCount":9},[],{"trials":1216,"activeCount":9},[],{"intervention":168,"totalTrials":329,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":9},[],{"trials":1222,"activeCount":9},[],{"trials":1224,"activeCount":9},[1225],{"nctId":160,"briefTitle":161,"status":141,"phases":1226,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":1227,"interventions":1228},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":1230,"activeCount":9},[],{"trials":1232,"activeCount":9},[],{"trials":1234,"activeCount":9},[],{"intervention":171,"totalTrials":329,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":9},[],{"trials":1240,"activeCount":9},[],{"trials":1242,"activeCount":9},[1243],{"nctId":160,"briefTitle":161,"status":141,"phases":1244,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":1245,"interventions":1246},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":1248,"activeCount":9},[],{"trials":1250,"activeCount":9},[],{"trials":1252,"activeCount":9},[],{"intervention":172,"totalTrials":329,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":9},[],{"trials":1258,"activeCount":9},[],{"trials":1260,"activeCount":9},[1261],{"nctId":160,"briefTitle":161,"status":141,"phases":1262,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":1263,"interventions":1264},[87,88],[15],[59,168,169,170,147,171,172,158],{"trials":1266,"activeCount":9},[],{"trials":1268,"activeCount":9},[],{"trials":1270,"activeCount":9},[],{"intervention":194,"totalTrials":329,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1274,"activeCount":9},[],{"trials":1276,"activeCount":9},[],{"trials":1278,"activeCount":9},[1279],{"nctId":185,"briefTitle":186,"status":176,"phases":1280,"primaryCompletion":188,"completion":188,"start":189,"enrollment":110,"conditions":1281,"interventions":1282},[87,88],[191],[193,194,195,196,59,197],{"trials":1284,"activeCount":9},[],{"trials":1286,"activeCount":9},[],{"trials":1288,"activeCount":9},[],{"intervention":195,"totalTrials":329,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":9},[],{"trials":1294,"activeCount":9},[],{"trials":1296,"activeCount":9},[1297],{"nctId":185,"briefTitle":186,"status":176,"phases":1298,"primaryCompletion":188,"completion":188,"start":189,"enrollment":110,"conditions":1299,"interventions":1300},[87,88],[191],[193,194,195,196,59,197],{"trials":1302,"activeCount":9},[],{"trials":1304,"activeCount":9},[],{"trials":1306,"activeCount":9},[],{"intervention":196,"totalTrials":329,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1310,"activeCount":9},[],{"trials":1312,"activeCount":9},[],{"trials":1314,"activeCount":9},[1315],{"nctId":185,"briefTitle":186,"status":176,"phases":1316,"primaryCompletion":188,"completion":188,"start":189,"enrollment":110,"conditions":1317,"interventions":1318},[87,88],[191],[193,194,195,196,59,197],{"trials":1320,"activeCount":9},[],{"trials":1322,"activeCount":9},[],{"trials":1324,"activeCount":9},[],{"intervention":1326,"totalTrials":329,"cells":1327},"Glucose\u002FAmino acids",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1336,"NA":1338},{"trials":1329,"activeCount":9},[],{"trials":1331,"activeCount":9},[],{"trials":1333,"activeCount":9},[],{"trials":1335,"activeCount":9},[],{"trials":1337,"activeCount":9},[],{"trials":1339,"activeCount":9},[1340],{"nctId":1341,"briefTitle":1342,"status":176,"phases":1343,"primaryCompletion":1344,"completion":1345,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1349},"NCT04425642","Effects of Parenteral Nutrition in HSCT",[91],"2020-11-01","2021-06-01","2020-02-01",120,[1172],[1326,1350],"Glucose\u002FAmino acids\u002FLipids",{"intervention":1350,"totalTrials":329,"cells":1352},{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1354,"activeCount":9},[],{"trials":1356,"activeCount":9},[],{"trials":1358,"activeCount":9},[],{"trials":1360,"activeCount":9},[],{"trials":1362,"activeCount":9},[],{"trials":1364,"activeCount":9},[1365],{"nctId":1341,"briefTitle":1342,"status":176,"phases":1366,"primaryCompletion":1344,"completion":1345,"start":1346,"enrollment":1347,"conditions":1367,"interventions":1368},[91],[1172],[1326,1350],{"intervention":1370,"totalTrials":329,"cells":1371},"Anticonvulsants",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1373,"activeCount":9},[],{"trials":1375,"activeCount":9},[],{"trials":1377,"activeCount":9},[],{"trials":1379,"activeCount":9},[],{"trials":1381,"activeCount":9},[],{"trials":1383,"activeCount":9},[1384],{"nctId":1385,"briefTitle":1386,"status":176,"phases":1387,"conditions":1388,"interventions":1394},"NCT00241995","Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome",[91],[1389,1390,1391,1392,1393],"Topiramate","Lamotrigine","Memnatine","Diazepam","Placebo",[1370],{"intervention":1396,"totalTrials":329,"cells":1397},"Rituximab, Cyclophosphamide, and Corticosteroids",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1406,"NA":1408},{"trials":1399,"activeCount":9},[],{"trials":1401,"activeCount":9},[],{"trials":1403,"activeCount":9},[],{"trials":1405,"activeCount":9},[],{"trials":1407,"activeCount":9},[],{"trials":1409,"activeCount":9},[1410],{"nctId":1411,"briefTitle":1412,"status":105,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":814,"conditions":1416,"interventions":1418},"NCT05679336","Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy",[91],"2024-08-31","2018-05-01",[1417],"Membranous Nephropathy - PLA2R Induced",[1396]]